Intercept Pharmaceuticals
Our mission is to build a healthier tomorrow for patients with rare and serious liver diseases.
Morristown, United States
376 employees
Post Ipo Debt
Total: $970.05M
Biotechnology, Health Care +1
General Information
Get notified when Intercept Pharmaceuticals moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Intercept Pharmaceuticals
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
United States Market
Biotechnology
About Intercept Pharmaceuticals
Taxonomy: Biopharmaceutical, Liver diseases, Rare diseases, Drug development, Therapeutics, Chronic autoimmune liver diseases, Small molecule drugs, Fibrotic diseases, Metabolic diseases, Bile acid receptors, Chronic liver diseases, Non-viral liver diseases, Innovation
Funding Rounds & Investors (8)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post-IPO Debt | •••••• | - | 30 Jun 2016 | |
| Post-IPO Equity | •••••• | - | 01 Apr 2015 | |
| Post-IPO Equity | •••••• | - | 17 Jun 2013 | |
| Series C | •••••• | 3 |
|
10 Aug 2012 |
| Series B | •••••• | 1 |
|
25 Jan 2010 |
Latest News
View All
Intercept Pharmaceuticals Alternatives & Competitors
Developing therapeutics for diseases with impaired kidney function
Pioneering breakthroughs in genetic disorders and liver diseases using RNA interference technology.
Madrigal is focused on delivering novel therapeutics for MASH, a serious liver disease.
vs
Altimmune, Inc.
FAQ About Intercept Pharmaceuticals
Don't just browse. Track.
Signal Tracker monitors Intercept Pharmaceuticals and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.
